Cargando…

Precise druggability of the PTH type 1 receptor

Class B G protein-coupled receptors (GPCRs) are notoriously difficult to target by small molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain limits the identification and development of non-peptide small molecule ligands. Using the parathyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutkeviciute, Ieva, Lee, Ji Young, White, Alex D., Maria, Christian Santa, Peña, Karina A., Savransky, Sofya, Doruker, Pemra, Li, Hongchun, Lei, Saifei, Kaynak, Burak, Tu, Chialing, Clark, Lisa J., Sanker, Subramaniam, Gardella, Thomas J., Chang, Wenhan, Bahar, Ivet, Vilardaga, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891041/
https://www.ncbi.nlm.nih.gov/pubmed/34949836
http://dx.doi.org/10.1038/s41589-021-00929-w
Descripción
Sumario:Class B G protein-coupled receptors (GPCRs) are notoriously difficult to target by small molecules because their large orthosteric peptide-binding pocket embedded deep within the transmembrane domain limits the identification and development of non-peptide small molecule ligands. Using the parathyroid hormone type 1 receptor (PTHR) as a prototypic class B GPCR target, and a combination of molecular dynamics simulations and elastic network model-based methods, we demonstrate that PTHR druggability can be effectively addressed. Here we found a key mechanical site that modulates the collective dynamics of the receptor and used this ensemble of PTHR conformers to identify selective small molecules with strong negative allosteric and biased properties for PTHR signaling in cell and PTH actions in vivo. This study provides a computational pipeline to detect precise druggable sites and identify allosteric modulators of PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic candidates.